Myc Proto Oncogene Protein - Pipeline Insight, 2025

This “Myc Proto Oncogene Protein - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Myc Proto Oncogene Protein pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Myc Proto Oncogene Protein: Understanding

Myc Proto Oncogene Protein: Overview

The Myc proto-oncogene proteins are key regulators in cellular biology, crucial for maintaining normal cell functions and growth. Their importance extends to both health and disease, as alterations in their expression or activity are frequently associated with the development of various cancers. Given their central role in cell biology, understanding the function and regulation of Myc proteins is critical for developing new therapeutic strategies to combat cancer and other diseases related to cell proliferation and survival.

The Myc proto-oncogene proteins are characterized by their distinctive structure, which includes a basic helix-loop-helix-leucine zipper (bHLH-LZ) domain. This domain is essential for dimerization with partner proteins and for binding to specific DNA sequences, enabling the regulation of target gene expression. Additionally, Myc proteins contain transactivation domains that facilitate interactions with other transcriptional regulators and components of the transcriptional machinery. The structural configuration of Myc proteins is integral to their function, allowing them to modulate a broad spectrum of cellular processes.

The mechanism of Myc proto-oncogene proteins involves their role as transcription factors that regulate gene expression by binding to specific DNA sequences known as E-boxes. Upon binding, Myc proteins recruit co-factors and other components of the transcriptional machinery to activate or repress the transcription of target genes involved in cell growth, proliferation, and apoptosis. They often form heterodimers with partner proteins, such as Max, which is crucial for their DNA-binding activity and functional specificity. Additionally, Myc proteins influence various cellular pathways, including those related to metabolism, ribosome biogenesis, and cellular stress responses. Dysregulation of this mechanism, through overexpression, gene amplification, or mutation, can disrupt normal cellular homeostasis, leading to uncontrolled cell division, genomic instability, and tumorigenesis. This makes Myc proteins central figures in both the regulation of normal cell function and the pathogenesis of cancer.

The role of Myc proto-oncogene proteins is fundamental in orchestrating a myriad of cellular processes critical for normal growth, development, and homeostasis. Acting as potent transcription factors, Myc proteins govern the expression of genes involved in cell cycle progression, metabolism, apoptosis, and differentiation. Their ability to finely tune gene expression programs enables them to exert profound effects on cellular fate, influencing everything from cell proliferation to tissue morphogenesis. However, dysregulation of Myc proteins, often observed in cancer, leads to aberrant gene expression patterns, driving uncontrolled cell proliferation and tumorigenesis. Thus, understanding the multifaceted role of Myc proteins is pivotal not only for unraveling the intricacies of normal cellular physiology but also for devising targeted therapies to combat cancer and other diseases stemming from Myc dysregulation.

“Myc Proto Oncogene Protein - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myc Proto Oncogene Protein pipeline landscape is provided which includes the disease overview and Myc Proto Oncogene Protein treatment guidelines. The assessment part of the report embraces, in depth Myc Proto Oncogene Protein commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myc Proto Oncogene Protein collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myc Proto Oncogene Protein R&D. The therapies under development are focused on novel approaches to treat/improve Myc Proto Oncogene Protein.

Myc Proto Oncogene Protein Emerging Drugs Chapters

This segment of the Myc Proto Oncogene Protein report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myc Proto Oncogene Protein Emerging Drugs

RRx-001: EpicentRx

RRx-001 is a first-in-class, minimally toxic small molecule immunotherapeutic that inhibits cMyc, downregulates the antiphagocytic checkpoint, CD47, repolarizes tumor associated macrophages (TAM) from protumor M2 to antitumor M1 and resensitizes to previously active first line therapies. RRx-001, is among a portfolio of immunotherapeutic compounds that normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies in small cell lung cancer (SCLC), glioblastoma, colorectal cancer and additional cancers. RRx-001 is designed to be used either as a monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy.

Cabozantinib is being developed by EpicentRx and is currently in Phase III for Small Cell Lung Cancer. The drug is also being developed for the treatment of Solid tumors, Oral Mucositis, Head & Neck Cancer (HNC), Metastatic Colorectal Cancer (mCRC), Endometriosis, Parkinson’s, ALS/MND and others.

WP1066: Moleculin Biotech, Inc.

WP1066 is an oral p-STAT3 inhibitor that has been studied in various clinical trials and preclinical models for its potential therapeutic applications in cancer treatment. WP1066 is an analog of caffeic acid that inhibits the phosphorylation of p-STAT3, a key transcription factor involved in cancer cell growth and survival. This targeted approach aims to minimize side effects and improve treatment outcomes. The drug is in the Phase II stage of development for the treatment of Glioblastoma.

OTX-2002: Omega Therapeutics

OTX-2002 is an investigational mRNA therapeutic being developed by Omega Therapeutics. OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for two independent epigenomic controllers. It is designed to downregulate MYC expression, a master transcription factor that plays a significant role in over 50% of human cancers. It is currently in Phase I/II stage of clinical trial evaluation for the treatment of Hepatocellular Carcinoma.

Myc Proto Oncogene Protein: Therapeutic Assessment

This segment of the report provides insights about the different Myc Proto Oncogene Protein drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myc Proto Oncogene Protein

There are approx. 12+ key companies which are developing the therapies for Myc Proto Oncogene Protein. The companies which have their Myc Proto Oncogene Protein drug candidates in the most advanced stage, i.e. Phase III include, EpicentRx.

Phases

The report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myc Proto Oncogene Protein pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myc Proto Oncogene Protein: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myc Proto Oncogene Protein therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myc Proto Oncogene Protein drugs.

Myc Proto Oncogene Protein Report Insights

• Myc Proto Oncogene Protein Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myc Proto Oncogene Protein Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myc Proto Oncogene Protein drugs?
• How many Myc Proto Oncogene Protein drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myc Proto Oncogene Protein?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myc Proto Oncogene Protein therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myc Proto Oncogene Protein and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• EpicentRx
• Moleculin Biotech, Inc.

Omega Therapeutics

• Cothera Bioscience, Inc
• Aravive

Key Products

• RRx-001
• WP1066
• OTX-2002
• PC-002
• CA106T

This product will be delivered within 2 business days.